Overview
Cerebrolysin is a cognitive-focused compound. Porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids.
With a half-life of ~30 minutes, Cerebrolysin requires daily administration in most observed protocols. Administered via IM injection, it has a bioavailability of approximately 100% via its primary route.
Active peptide fractions have half-lives of approximately 15–60 minutes. Intramuscular administration. One-compartment model.
Mechanism of Action
Cerebrolysin's pharmacological activity involves the following key pathways:
Neurotrophin Modulation
Cerebrolysin interacts with central nervous system pathways involved in neuroplasticity and cognitive function.
CNS Penetration
Cerebrolysin reaches the central nervous system through its administered route.
Dosing Protocols
The following protocols represent commonly observed dosing patterns. These are observational summaries, not recommendations.
Dose
5 mL/day
Route
Intramuscular
Frequency
2-3 times daily
Duration
4-12 weeks
Dose
30 mL/day
Route
Intramuscular
Frequency
2-3 times daily
Duration
4-12 weeks
Frequently Asked Questions
What is Cerebrolysin and what is it used for?
Cerebrolysin is a complex neuropeptide preparation derived from enzymatically processed porcine brain proteins, consisting of low-molecular-weight peptide fragments and free amino acids all below 10 kilodaltons in size. It is approved in multiple European and Asian countries for stroke rehabilitation, traumatic brain injury (TBI), and Alzheimer's disease, and is widely used in biohacking and nootropic communities for cognitive enhancement and neuroprotection. Its peptide fragments are small enough to cross the blood–brain barrier and directly mimic the action of endogenous neurotrophic factors.
How does Cerebrolysin work to enhance cognition?
Cerebrolysin contains peptide fragments that mimic the activity of endogenous neurotrophic factors including BDNF, NGF, CNTF, and GDNF, supporting neuronal survival, synaptic plasticity, and neurogenesis in the hippocampus. It has also been observed to reduce excitotoxicity, inhibit free radical formation, suppress apoptosis, and stimulate neurogenesis – making it one of the most mechanistically broad neuroprotective agents available. These multi-target properties are thought to underlie the cognitive and memory improvements observed in clinical trials.
What is the half-life of Cerebrolysin?
The complexity of Cerebrolysin's composition makes standard pharmacokinetic analysis of individual components difficult. Individual peptide components have half-lives in the range of minutes – for example, BDNF has a plasma half-life of approximately 10 minutes – but Cerebrolysin is considered to act as a balanced, polyfunctional mixture rather than as individual compounds. Functional effects and clinical benefit are typically observed to persist for days to weeks beyond the injection cycle, suggesting downstream gene expression changes and structural neuroplasticity.
How is Cerebrolysin administered and what are common doses?
Cerebrolysin comes as a pre-mixed, ready-to-use sterile solution in glass ampoules and requires either intramuscular (IM) or intravenous (IV) injection. Doses of up to 5 mL can be administered undiluted via slow IM injection over approximately 3 minutes. For cognitive enhancement, community protocols commonly involve 5 mL daily IM injections over cycles of 10–20 consecutive days. Higher IV doses (10–30 mL) are used in clinical stroke and TBI settings and require dilution in saline or Ringer's solution.
How long does Cerebrolysin take to work?
In clinical trials for Alzheimer's disease, 4-week daily treatment cycles have been observed to produce measurable cognitive improvements that persist for several months after the injection cycle ends. In community nootropic protocols, users commonly report cognitive clarity and improved memory consolidation within the first 1–2 weeks of a cycle, with cumulative benefit building over the full 20-day protocol. The carryover of effects after cycle completion is a distinctive characteristic of Cerebrolysin noted in multiple clinical studies.
Can Cerebrolysin be stacked with Semax or Selank?
Cerebrolysin is frequently combined with Semax and Selank in community and clinical nootropic protocols. The rationale is mechanistic complementarity: Semax primarily upregulates endogenous BDNF production, Selank manages the GABAergic and anxiolytic layer, and Cerebrolysin provides an exogenous supply of peptide fragments that directly mimic multiple neurotrophic factors simultaneously. The combination is commonly described as providing the most comprehensive neuroplasticity-supporting stack available among peptide compounds.